Conference Call Details: | |
Toll Free: | 855-327-6837 |
International: | 631-891-4304 |
Conference ID: | 10017178 |
Webcast: | https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX |
A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the conference call.
About
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes FMX114 for the treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the treatment of major immuno-inflammatory conditions and rare skin diseases.
For more information about
Investor Relations:
617-430-7582
joer@lifesciadvisors.com
Chief Financial Officer
908-458-9106
tyler.zeronda@vynetx.com
Source:
2021 GlobeNewswire, Inc., source